Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
With over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
With deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
Get a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Recombinant monoclonal antibody to Human IL1 beta. Canakinumab (INN, trade name Ilaris, previously ACZ885) is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha. Canakinumab was for the treatment of rheumatoid arthritis. Canakinumab is as a possible treatment for chronic obstructive pulmonary disease, gout and coronary artery disease.
Target
IL1 beta
Type
IgG1 - kappa
Immunogen
Recombinant human ILI beta
Species Reactivity
Human
Expression Host
CHO
Applications
Suitable for use in FC, IP, ELISA, Neut, FuncS, IF, IHC and most other immunological methods.
CAS
914613-48-2
Trade name
ilaris
Specific Activity
Tested positive against native human antigen
Predicted N terminal
H Chain: EVQLVQSL Chain: EIVLTQS
Purity
Purity >95% by SDS-PAGE.
Size
1mg
Storage
Store at -20°C. Avoid multiple freeze/thaw cycles.
BACKGROUND
Antigen Description
Produced by activated macrophages, IL1 stimulates thymocyte proliferation by inducing IL2 release, B-cell maturation and proliferation, and fibroblast growth factor activity. IL1 proteins are involved in the inflammatory response, being identified as endogenous pyrogens, and are reported to stimulate the release of prostaglandin and collagenase from synovial cells.
Function
cytokine activity; growth factor activity; interleukin-1 receptor binding; protein domain specific binding